450 related articles for article (PubMed ID: 25704014)
1. Role of sigma-1 receptors in neurodegenerative diseases.
Nguyen L; Lucke-Wold BP; Mookerjee SA; Cavendish JZ; Robson MJ; Scandinaro AL; Matsumoto RR
J Pharmacol Sci; 2015 Jan; 127(1):17-29. PubMed ID: 25704014
[TBL] [Abstract][Full Text] [Related]
2. Sigma receptors as potential therapeutic targets for neuroprotection.
Nguyen L; Kaushal N; Robson MJ; Matsumoto RR
Eur J Pharmacol; 2014 Nov; 743():42-7. PubMed ID: 25261035
[TBL] [Abstract][Full Text] [Related]
3. Sigma-1 Receptors and Neurodegenerative Diseases: Towards a Hypothesis of Sigma-1 Receptors as Amplifiers of Neurodegeneration and Neuroprotection.
Nguyen L; Lucke-Wold BP; Mookerjee S; Kaushal N; Matsumoto RR
Adv Exp Med Biol; 2017; 964():133-152. PubMed ID: 28315269
[TBL] [Abstract][Full Text] [Related]
4. The involvement of the sigma-1 receptor in neurodegeneration and neurorestoration.
Ruscher K; Wieloch T
J Pharmacol Sci; 2015 Jan; 127(1):30-5. PubMed ID: 25704015
[TBL] [Abstract][Full Text] [Related]
5. The cholinergic system, sigma-1 receptors and cognition.
van Waarde A; Ramakrishnan NK; Rybczynska AA; Elsinga PH; Ishiwata K; Nijholt IM; Luiten PG; Dierckx RA
Behav Brain Res; 2011 Aug; 221(2):543-54. PubMed ID: 20060423
[TBL] [Abstract][Full Text] [Related]
6. The Role of Sigma 1 Receptor as a Neuroprotective Target in Glaucoma.
Mysona B; Kansara N; Zhao J; Bollinger K
Adv Exp Med Biol; 2017; 964():299-307. PubMed ID: 28315279
[TBL] [Abstract][Full Text] [Related]
7. Emerging Benefits: Pathophysiological Functions and Target Drugs of the Sigma-1 Receptor in Neurodegenerative Diseases.
Wu NH; Ye Y; Wan BB; Yu YD; Liu C; Chen QJ
Mol Neurobiol; 2021 Nov; 58(11):5649-5666. PubMed ID: 34383254
[TBL] [Abstract][Full Text] [Related]
8. mGlu3 receptor and astrocytes: partners in neuroprotection.
Durand D; Carniglia L; Caruso C; Lasaga M
Neuropharmacology; 2013 Mar; 66():1-11. PubMed ID: 22564439
[TBL] [Abstract][Full Text] [Related]
9. Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders.
Hayashi T; Tsai SY; Mori T; Fujimoto M; Su TP
Expert Opin Ther Targets; 2011 May; 15(5):557-77. PubMed ID: 21375464
[TBL] [Abstract][Full Text] [Related]
10. Protective role of melatonin in domoic acid-induced neuronal damage in the hippocampus of adult rats.
Ananth C; Gopalakrishnakone P; Kaur C
Hippocampus; 2003; 13(3):375-87. PubMed ID: 12722978
[TBL] [Abstract][Full Text] [Related]
11. Excitotoxic damage, disrupted energy metabolism, and oxidative stress in the rat brain: antioxidant and neuroprotective effects of L-carnitine.
Silva-Adaya D; Pérez-De La Cruz V; Herrera-Mundo MN; Mendoza-Macedo K; Villeda-Hernández J; Binienda Z; Ali SF; Santamaría A
J Neurochem; 2008 May; 105(3):677-89. PubMed ID: 18194214
[TBL] [Abstract][Full Text] [Related]
12. Sigma 1 receptor: A novel therapeutic target in retinal disease.
Smith SB; Wang J; Cui X; Mysona BA; Zhao J; Bollinger KE
Prog Retin Eye Res; 2018 Nov; 67():130-149. PubMed ID: 30075336
[TBL] [Abstract][Full Text] [Related]
13. Cellular pathways leading to neuronal dysfunction and degeneration.
Kazantsev AG
Drug News Perspect; 2007 Oct; 20(8):501-9. PubMed ID: 18080037
[TBL] [Abstract][Full Text] [Related]
14. Sigma-1 (σ
Maurice T; Goguadze N
Handb Exp Pharmacol; 2017; 244():81-108. PubMed ID: 28275911
[TBL] [Abstract][Full Text] [Related]
15. Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders.
Maurice T
Expert Opin Drug Discov; 2021 Apr; 16(4):373-389. PubMed ID: 33070647
[No Abstract] [Full Text] [Related]
16. Targeting reactive astrogliosis by novel biotechnological strategies.
Colangelo AM; Cirillo G; Lavitrano ML; Alberghina L; Papa M
Biotechnol Adv; 2012; 30(1):261-71. PubMed ID: 21763415
[TBL] [Abstract][Full Text] [Related]
17. Cellular responses following retinal injuries and therapeutic approaches for neurodegenerative diseases.
Cuenca N; Fernández-Sánchez L; Campello L; Maneu V; De la Villa P; Lax P; Pinilla I
Prog Retin Eye Res; 2014 Nov; 43():17-75. PubMed ID: 25038518
[TBL] [Abstract][Full Text] [Related]
18. Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain.
Brimson JM; Brimson S; Chomchoei C; Tencomnao T
Expert Opin Ther Targets; 2020 Oct; 24(10):1009-1028. PubMed ID: 32746649
[TBL] [Abstract][Full Text] [Related]
19. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
Calabrese V; Lodi R; Tonon C; D'Agata V; Sapienza M; Scapagnini G; Mangiameli A; Pennisi G; Stella AM; Butterfield DA
J Neurol Sci; 2005 Jun; 233(1-2):145-62. PubMed ID: 15896810
[TBL] [Abstract][Full Text] [Related]
20. Neurotrophic molecules: strategies for designing effective therapeutic molecules in neurodegeneration.
Skaper SD; Walsh FS
Mol Cell Neurosci; 1998 Nov; 12(4-5):179-93. PubMed ID: 9828084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
